Tirzepatide
The dual agonist behind Mounjaro, at research-grade pricing — the compound that reset expectations in this category.
Dual GIP/GLP-1 receptor agonist studied for weight loss and blood sugar control.
- Also known as
- LY3298176; brand names Mounjaro and Zepbound
- Class
- Dual GIP and GLP-1 receptor agonist
- Evidence
- Approved medicine
- FDA
- Approved for type 2 diabetes (2022) and weight management (2023)
- WADA 2026
- Not prohibited
Concentrations · 1 vial
from R 1 50030mg selected — in stock and shipping now.
About Tirzepatide
Tirzepatide acts on two incretin receptors, GLP-1 and GIP. The GLP-1 half is the familiar mechanism: slowed gastric emptying, increased satiety, improved glycaemic control. The GIP half is what tirzepatide added, and adding it produced results in trials that were clearly larger than semaglutide's — enough to make it the reference compound in the category almost immediately.
Mounjaro is the registered brand of tirzepatide in South Africa; this vial is unbranded tirzepatide, not a registered medicine. The Learn article on tirzepatide in South Africa covers local availability and what the medical aid position actually is, which is usually the other half of the question.
Specifications
Evidence level: Approved medicine · FDA-approved as Mounjaro (type 2 diabetes, 2022) and Zepbound (weight management, 2023).
- Structure
- 39-amino-acid modified peptide with a C20 fatty diacid side chain
- Formula
- C225H348N48O68 PubChem ↗
- Molecular weight
- 4813 g/mol
- CAS number
- 2023788-19-2
- Half-life
- About 5 days (FDA label)
What it’s researched for
Research context, not medical advice. Everything we sell is supplied for research purposes.
Dual GIP/GLP-1 agonism
Two incretin receptors rather than one, which is the difference between tirzepatide and semaglutide and the reason the trial results separated.
Weight reduction
The endpoint that made it the reference compound in this class, with a substantial and well-replicated clinical literature behind it.
Blood sugar
Glycaemic control is where the incretin class started, and tirzepatide's data on it is as strong as its weight data.
What the research does not show
The limits of the evidence, stated as plainly as the findings.
- That a research vial is the same as the registered medicine. It is a different, unregistered product.
- Long-term outcomes outside the trial populations.
Reconstitution and storage
The 30mg vial reconstituted with 3 mL of bacteriostatic water gives a concentration of 10mg/mL. Unopened vials are stable at room temperature in transit but belong in a fridge once they arrive, and out of a parked car in a Highveld summer.
Questions we get about Tirzepatide
Sources
- Coskun T, Sloop KW, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism, 2018.
- Jastreboff AM, Aronne LJ, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
- Frias JP, Davies MJ, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine, 2021.
- US Food and Drug Administration. MOUNJARO (tirzepatide) prescribing information. FDA label, 2022.
Often bought with it
Order Tirzepatide in South Africa
Everything ships from Johannesburg, nationwide. Add it to your order slip, send the slip on WhatsApp, and we’ll confirm stock, pricing and delivery before you pay a cent.